|Day Low/High||165.68 / 167.05|
|52 Wk Low/High||114.27 / 197.00|
-- Television Personality is Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --
In this day and age, companies must be 'disruptors' or get left in the dust.
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.
Jim Cramer's watching six stocks to determine when the selling will end.
Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.
David Tepper's Appaloosa LP renews calls for changes at the top.
Allergan wants Botox licenses for pediatric patients.
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
I still believe it will be a big year for buyouts across the biotech industry.
Net income declines to EUR 253 million reflecting unfavorable market movements and other charges Underlying earnings decrease by 8% to EUR 1,010 million, as lower Retirement Plans earnings in the US more than offset business growth and higher margins in...
Aegon has set new medium-term financial targets with a focus on growing capital generation and dividends.
Shares of the Botox competitor could correct/consolidate after a recent surge.
Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.
Right now it feels as though everyone sees the obvious resistance and overbought situation.
Shares of Botox maker Allergan slipped after a billionaire hedge-fund manager challenges the company's management.
Evolus surges Monday after the U.S. Food and Drug Administration approves the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.
AGN, AVA, ALK, RLI and CRT all recently were downgraded by TheStreet's Quant Ratings.
Clearly, the first half of the month shaped up better than the second half.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, CATS, EXTR, LAD Downgrades: AGN Initiations: LBC, MRBK, SBT Read on to get TheStreet Quant Ratings' detailed report:
Kate Warne, investment strategist at Edward Jones, talked to TheStreet about what Boeing's report means for U.S. companies with exposure to China, Apple's beat and how the healthcare sector is looking.
Botox maker reports a fourth-quarter loss of $4.3 billion, a reversal from a year-earlier profit of $3.05 billion.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Eight important companies report earnings between Monday and Tuesday. Don't miss them.
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
Jim Cramer's plan for getting through the heart of earnings season next week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.